Research peptides and UK law (educational overview)

What "research use only" actually means

"Research use only" is a labelling category, not a personal-use category. It signals that a compound is supplied for laboratory and analytical work within an authorised research framework, and that it has not been assessed by a medicines regulator (MHRA, EMA, FDA) for human therapeutic safety, quality or efficacy. It is not a workaround for the prescription-only or unlicensed-medicine rules that apply to human use.

The authorised-research framework

Genuine research with peptide compounds in the UK ordinarily involves a layered governance framework that may include some or all of the following, depending on whether the work is in vitro, ex vivo, on animals, or on humans:

• Institutional ethics approval (Research Ethics Committee, where applicable).
• Medicines and Healthcare products Regulatory Agency clinical trial authorisation, where the work is a clinical trial of an investigational medicinal product (CTIMP).
• Home Office authorisation for animal research (ASPA 1986).
• Health and Safety Executive considerations for hazardous materials.
• Institutional standard operating procedures, biosafety oversight, and material transfer documentation.
• Documented provenance for any compound entering the laboratory, with certificate-of-analysis and chain-of-custody records.

What this site does not do

• It does not list, rank or recommend suppliers of research peptides.
• It does not provide procurement, sourcing, import or shipping advice.
• It does not provide instructions for reconstitution, dosing or administration.
• It does not advise on personal use of any peptide for any indication.

For the lab-governance context only, see laboratory procurement governance. That page is institutional and not a step-by-step procurement guide.

Why we distinguish "research-use" from human use

A compound supplied as "research use only" may have variable identity, purity, sterility and dosing accuracy. There is no MHRA pharmacovigilance for its human administration. Adverse events have no regulator-monitored signal pathway. Counterfeit and grey-market products are common. The legal, scientific and safety reasons for not crossing the line from research use to personal use all point in the same direction. See grey-market peptides in the UK and counterfeit weight-loss pens for the broader risk picture.